Table 1.
Author (Year) | Study Population (N) | Exposure | Findings |
---|---|---|---|
Bargman et al. (2001)33 | PD patients (CANUSA study) |
RKF UOP |
|
Shemin et al. (2001)36 | 114 prospective HD patients | RKF defined as renal urea clearance and renal creatinine clearance |
|
Paniagua et al. (2002)35 | PD patients (ADEMEX trial) |
RKF |
|
Termorshuizen et al. (2004)37 | 740 incident HD patients (NECOSAD cohort) |
RKF defined as renal Kt/V urea |
|
Vilar et al. (2009)23 | 650 incident HD patients | RKF defined as renal urea clearance |
|
Shafi et al. (2010)32 | 734 incident HD patients (CHOICE cohort) |
UOP |
|
Van der Wal et al. (2011)38 | 1191 incident HD patients & 609 incident PD patients (NECOSAD cohort) |
RKF defined as mean of renal urea and creatinine clearance |
|
Obi et al. (2016)34 | 6538 incident HD patients from an LDO | RKF defined as renal urea clearance UOP |
|
Abbreviations: PD, peritoneal dialysis; CANUSA, Canada-USA; RKF, residual kidney function; UOP, urine output; ADEMEX, Adequacy of Peritoneal Dialysis in Mexico; HD, hemodialysis; NECOSAD, Netherlands Cooperative Study on the Adequacy of Dialysis; CHOICE, Choices for Healthy Outcomes in Caring for End-Stage Renal Disease; ESA, erythropoietin-stimulating agent; LDO, large dialysis organization.